Pre-operative Prophylaxis With Vancomycin and Cefazolin in Pediatric Cardiovascular Surgery Patients
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The investigators hope to learn 1) if the addition of prophylaxis with vancomycin will
decrease the rate of cefazolin non-susceptible surgical site infections (SSI), in high risk
population 2) to develop better understanding of vancomycin and cefazolin pharmacokinetics in
children undergoing cardiopulmonary bypass (CPB) 3) to assess the barriers to vancomycin
dosing peri-operatively 4) to assess side effects and risks associated with peri-operative
vancomycin administration. This will allow us to improve patient care by better understanding
the benefits or the risks of peri-operative vancomycin administration and potentially
decrease cefazolin-resistant surgical site infections.
In addition, this study gives us the opportunity to evaluate cefazolin and vancomycin
pharmacokinetics (pK) on children on CPB.
The investigators will take blood samples from 20 patients. In 10 patients the investigators
will do Cefazolin pK analysis and in the other 10 the investigators will do pK Vancomycin
analysis. For the remainder of 292 patients, only prospective chart review will be done to
determine the incidence of SSIs.
This data will be compared with 936 controls who received only Cefazolin pre-operatively as
prophylaxis for SSI's.
--------------------------------------------------------------------------------